Cadila Healthcare Limited Salmeterol Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Salmeterol Export Records India — #12 Exporter, 16 Shipments, $307.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Salmeterol

India Pharmaceutical Trade Intelligence

$72.8M148 Suppliers90 CountriesHS 30049099

ExportsIndia → CHILE13.4%India → TURKEY10.8%

#1 Supplier: CIPLA LIMITED #1 Buyer: PAYAZ BIOMEDIKAL

Cadila Healthcare Limited — Salmeterol Exporter #12 | $307.6K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Salmeterol Exporter Profile

Indian Pharmaceutical Exporter · #12 for Salmeterol · $307.6K export value · DGFT Verified

Cadila Healthcare Limited is the #12 Indian exporter of Salmeterol with $307.6K in export value and 16 verified shipments. Cadila Healthcare Limited holds a 0.4% market share in Salmeterol exports across 2 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Salmeterol Export Profile: Buyers & Destinations

Cadila Healthcare Limited Salmeterol export treemap — buyers and destination countries | TransData Nexus

Where Does Cadila Healthcare Limited Export Salmeterol?

Country	Value	Shipments	Share
VIETNAM	$187.1K	10	54.5%
PHILIPPINES	$156.1K	7	45.5%

Cadila Healthcare Limited exports Salmeterol to 2 countries. The largest destination is VIETNAM accounting for 54.5% of Cadila Healthcare Limited's Salmeterol shipments. These destinations reflect Cadila Healthcare Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Salmeterol from Cadila Healthcare Limited?

Buyer	Country

What Salmeterol Formulations Does Cadila Healthcare Limited Export?

Product Description / Formulation	Value	Shipments
FORAIR 250 SALMETEROL & FLUTICASONE PROPIONATE INHALATION INHALER 1X120 MDI	$111.3K	5
FORAIR 250 SALMETEROL & FLUTICASONE PRO	$54.3K	3
FORAIR 250 INHALER CFC FREE SALMETEROL	$47.7K	2
FORAIR 250 INHALER SALMETEROL AND FLUTI	$35.3K	1
FORAIR 125 INHALER SALMETEROL AND FLUTICASONE PROPIONATE INHALER 1X120MDI	$32.2K	2
FORAIR 250 INHALER SALMETEROL AND FLUTICASONE PROPIONATE INHALER 1X120MDI	$23.5K	1
FORAIR 125 INHALER SALMETEROL AND FLUTI	$17.4K	1
FORAIR 125 SALMETEROL & FLUTICASONE PROPIONATE INHALATION INHALER CFC FREE 1X 1 UNIT	$10.8K	1
FORAIR 125 SALMETEROL & FLUTICASONE PROPIONATE INHALATION 120 METER DOSE 1 X 1UNIT	$10.6K	1

Cadila Healthcare Limited exports 9 distinct Salmeterol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FORAIR 250 SALMETEROL & FLUTICASONE PROPIONATE INHALATION IN with 5 shipments worth $111.3K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does Cadila Healthcare Limited Compare to Nearest Salmeterol Exporters?

Exporters ranked immediately above and below #12 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
10	LLOYD LABORATORIES PRIVATE LIMITED	$392.8K	11	1	$35.7K
11	KOPRAN LIMITED	$392.3K	9	1	$43.6K
12	CADILA HEALTHCARE LIMITED ★	$307.6K	16	2	$19.2K
13	POLLOMI PHARMACEUTICAL PRIVATE LIMITED	$245.0K	6	1	$40.8K
14	PRIME PHARMACEUTICALS PRIVATE LIMITED	$215.3K	21	2	$10.3K

Cadila Healthcare Limited ranks #12 among 148 Indian Salmeterol exporters. Average shipment value of $19.2K compared to the market average of $465.4K. The closest competitors by value are LLOYD LABORATORIES PRIVATE LIMITED and KOPRAN LIMITED.

Which Indian Ports Ship Salmeterol Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	1,431	20.4%
SAHAR AIR	1,278	18.2%
DELHI AIR	1,169	16.7%
SAHAR AIR CARGO ACC (INBOM4)	633	9.0%
NHAVA SHEVA SEA (INNSA1)	405	5.8%
Delhi Air	309	4.4%
Bombay Air	228	3.3%
JNPT/ NHAVA SHEVA SEA	191	2.7%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Salmeterol Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Salmeterol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 17 individual customs records matching Cadila Healthcare Limited exporting Salmeterol, covering 9 formulations to 2 countries via 4 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 90+ countries, 370+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Salmeterol

Salmeterol

Cadila Healthcare Limited — Salmeterol Exporter Profile

Cadila Healthcare Limited — Salmeterol Export Profile: Buyers & Destinations

Where Does Cadila Healthcare Limited Export Salmeterol?

Who Are the Top Buyers of Salmeterol from Cadila Healthcare Limited?

What Is India's Total Salmeterol Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Salmeterol Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Salmeterol Exporters?

What Salmeterol Formulations Does Cadila Healthcare Limited Export?

How Does Cadila Healthcare Limited Compare to Nearest Salmeterol Exporters?

Which Indian Ports Ship Salmeterol Exports?

What Other Respiratory Products Does Cadila Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Salmeterol Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Salmeterol Export Data from Cadila Healthcare Limited

Salmeterol Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source

ZYDUS HEALTHCARE PHILIPPINES INC	PHILIPPINES	$156.1K	7
HAPHARCOJ S CBRANCH	VIETNAM	$84.0K	4
HAPHARCO J S C BRANCH	VIETNAM	$54.3K	3
HAPHARCO J S C BRANCH CHI MINH CITY	VIETNAM	$48.8K	3